Compare · AMGN vs COEP
AMGN vs COEP
Side-by-side comparison of Amgen Inc. (AMGN) and Coeptis Therapeutics Holdings Inc. (COEP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and COEP operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN carries a market cap of $240.11B.
- AMGN has hit the wire 23 times in the past 4 weeks while COEP has been quiet.
- AMGN has more recent analyst coverage (25 ratings vs 0 for COEP).
- Company
- Amgen Inc.
- Coeptis Therapeutics Holdings Inc.
- Price
- -
- -
- Market cap
- $240.11B
- -
- 1M return
- +0.39%
- -
- 1Y return
- +28.49%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2020
- News (4w)
- 23
- 0
- Recent ratings
- 25
- 0
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- Securitize Tokenizes Anthropic Stock Onchain on First Day of Public Trading
- AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
- FDA Approval for KANJINTI issued to AMGEN INC
- Director Ishrak Omar was granted 152 shares, increasing direct ownership by 2% to 7,682 units (SEC Form 4)
- Director Holley Charles M was granted 185 shares, increasing direct ownership by 1% to 13,262 units (SEC Form 4)
- Director Gibbs David W was granted 278 shares (SEC Form 4)
- Director Drake Michael V was granted 114 shares, increasing direct ownership by 2% to 6,030 units (SEC Form 4)
- NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- FDA Approval for AMJEVITA issued to AMGEN INC
Latest COEP
- SEC Form 4 filed by Coeptis Therapeutics Holdings Inc.
- Chief Executive Officer Halabu David Elias converted options into 19,737 shares (SEC Form 4)
- Director Sohn Adam Craig converted options into 1,370 shares (SEC Form 4)
- Director Fuerst Bryan Eric converted options into 1,370 shares (SEC Form 4)
- Director Cooper Kenneth Lyle converted options into 1,370 shares (SEC Form 4)
- Chief Technology Officer Harris Jeffery Keeslar converted options into 12,444 shares (SEC Form 4)
- Chief Financial Officer Cogley Brian converted options into 4,112 shares, increasing direct ownership by 18% to 26,612 units (SEC Form 4)
- Amendment: Chief Marketing Officer Schadel Christopher Ryan bought $3,920 worth of shares (1,000 units at $3.92) and converted options into 3,169 shares (SEC Form 4)
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits